Developer docs
API playgroundTry for free, no card

Search company profiles

Spatz FGIA

Full company profile

uuid000gezv

Namestring
Spatz FGIA
Legal namestring
Spatz FGIA, Inc.
Websiteurl
spatzmedical.com
Company typeenum
Private
Founded yearint
2005
Descriptiontext

Spatz FGIA, Inc. is a U.S.-based medical device company headquartered in Great Neck, New York, focused on the development and commercialization of gastric balloon systems for non-surgical weight loss procedures. Founded in 2005, the company operates in the obesity treatment market alongside a small set of specialized competitors including Allurion Technologies, Apollo Endosurgery, and ReShape Lifesciences. Its core technology centers on advanced gastric balloon systems designed with improved safety and patient comfort characteristics compared to surgical bariatric alternatives, targeting healthcare providers and patients seeking minimally invasive obesity interventions.

The company employs between 51 and 100 people and is identified as a key market player actively investing in R&D to advance its product portfolio. Its proprietary focus is on the mechanical and clinical design of gastric balloon devices rather than software- or AI-driven capabilities. Distribution is presumed to follow the standard medical device model of selling to healthcare providers and clinical channels that administer the procedures to patients, though specific GTM mechanics, pricing, and reimbursement arrangements are not disclosed in the available data.

Spatz FGIA is a privately held company with no public ticker, no disclosed parent company, and no documented funding rounds. Operational data including revenue, ownership structure, management team, geographic footprint, and certification portfolio are not present in the provided sources, representing significant data gaps for any prospective investment diligence. The company's strategic posture as inferred from available evidence is that of a niche R&D-focused medical device specialist competing in a regulated, growing obesity treatment category.

Short descriptiontext

Spatz FGIA is a U.S. medical device company developing gastric balloon systems for non-surgical weight loss procedures. Founded in 2005 and based in Great Neck, NY, it serves healthcare providers and patients seeking minimally invasive obesity treatments.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersGreat Neck, United States
HQ citystring
Great Neck
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
gastric balloon devices, non-surgical weight loss, obesity treatment devices, minimally invasive weight loss, bariatric medical devices
NAICS code1 code
  • Surgical Appliance and Supplies Manufacturing339113
Product category
Medical Devices for Obesity Treatment
No data
Cost components5 values
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Spatz FGIA develops and manufactures advanced gastric balloon medical devices for non-surgical weight loss procedures. The company's products are designed with improved safety and patient comfort features to address rising obesity rates. Spatz FGIA, Inc. operates as a key market player in the gastric balloon segment alongside competitors such as Allurion Technologies Inc., Apollo Endosurgery, Inc., and ReShape Lifesciences, Inc.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Spatz FGIA is a medical device company focused on gastric balloon systems for non-surgical weight loss. The company develops advanced gastric balloon products designed to address obesity through minimally invasive procedures. Based on available information, Spatz FGIA operates in the gastric balloon market alongside competitors including Allurion Technologies Inc., Apollo Endosurgery, Inc., and ReShape Lifesciences, Inc.

Product and service1 record
1Advanced Gastric Balloon Systems
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Expansion highlight1 record

Each record includes

Type, Description

Peers10 records
1Boston Scientific
TypeBroad incumbent
Description

Acquired Apollo Endosurgery, bringing scale, sales force, and R&D resources to the endoscopic bariatric and gastric balloon category — overlapping end market and clinician relationships with Spatz FGIA.

2Medtronic
TypeBroad incumbent
Description

Broad medtech incumbent with metabolic/obesity franchise (including bariatric surgery and emerging diabetes/weight-loss adjacencies). Overlaps with Spatz FGIA in the obesity-treatment end market.

3Allurion Technologies
TypeDirect peer
Description

Direct competitor in the gastric balloon space, offering the Allurion (Elipse) swallowable, procedure-less balloon for non-surgical weight loss — directly comparable product and patient population to Spatz FGIA.

4Johnson & Johnson (Ethicon)
TypeBroad incumbent
Description

Major surgical and bariatric stapling franchise through Ethicon, targeting the same obesity-treatment patient population — though via surgical rather than endoscopic approaches.

5GI Dynamics
TypeEmerging player
Description

Developer of the EndoBarrier gastrointestinal liner for non-surgical weight loss and type 2 diabetes. Targets an overlapping patient population and minimally invasive obesity-treatment category.

6USGI Medical
TypeEmerging player
Description

Developer of endoscopic incisionless surgery tools used in bariatric and GI procedures — adjacent technology serving the same non-surgical obesity-treatment patient population as Spatz FGIA.

7ReShape Lifesciences
TypeDirect peer
Description

Direct competitor with a gastric balloon product (formerly ReShape and Obalon) targeting the same non-surgical weight-loss market as Spatz FGIA.

8BAROnova
TypeEmerging player
Description

Developer of the TransPyloric Shuttle, an endoscopic device for weight loss. Competes in the same non-surgical endoscopic obesity-treatment category as Spatz FGIA.

9Apollo Endosurgery
TypeDirect peer
Description

Direct competitor in gastric balloons (Orbera) and endoscopic bariatric devices, now part of Boston Scientific. Competes with Spatz FGIA in the same procedure category and patient base.

10Aspire Bariatrics
TypeEmerging player
Description

Developer of the AspireAssist aspiration therapy for non-surgical weight loss. Addresses the same obesity-treatment patient population as Spatz FGIA via a different minimally invasive mechanism.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Spatz FGIA

Medical Devices for Obesity Treatmentspatzmedical.com

Spatz FGIA is a U.S. medical device company developing gastric balloon systems for non-surgical weight loss procedures. Founded in 2005 and based in Great Neck, NY, it serves healthcare providers and patients seeking minimally invasive obesity treatments.

What Spatz FGIA does

Spatz FGIA, Inc. is a U.S.-based medical device company headquartered in Great Neck, New York, focused on the development and commercialization of gastric balloon systems for non-surgical weight loss procedures. Founded in 2005, the company operates in the obesity treatment market alongside a small set of specialized competitors including Allurion Technologies, Apollo Endosurgery, and ReShape Lifesciences. Its core technology centers on advanced gastric balloon systems designed with improved safety and patient comfort characteristics compared to surgical bariatric alternatives, targeting healthcare providers and patients seeking minimally invasive obesity interventions.

The company employs between 51 and 100 people and is identified as a key market player actively investing in R&D to advance its product portfolio. Its proprietary focus is on the mechanical and clinical design of gastric balloon devices rather than software- or AI-driven capabilities. Distribution is presumed to follow the standard medical device model of selling to healthcare providers and clinical channels that administer the procedures to patients, though specific GTM mechanics, pricing, and reimbursement arrangements are not disclosed in the available data.

Spatz FGIA is a privately held company with no public ticker, no disclosed parent company, and no documented funding rounds. Operational data including revenue, ownership structure, management team, geographic footprint, and certification portfolio are not present in the provided sources, representing significant data gaps for any prospective investment diligence. The company's strategic posture as inferred from available evidence is that of a niche R&D-focused medical device specialist competing in a regulated, growing obesity treatment category.

Spatz FGIA firmographics

Firmographics
Name
Spatz FGIA
Legal name
Spatz FGIA, Inc.
Website
https://spatzmedical.com
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
51–100 employees
Short description
Spatz FGIA is a U.S. medical device company developing gastric balloon systems for non-surgical weight loss procedures. Founded in 2005 and based in Great Neck, NY, it serves healthcare providers and patients seeking minimally invasive obesity treatments.
Ownership category
akta.pro rank

Where Spatz FGIA is headquartered

Location

Headquarters

HQ city
Great Neck
HQ country
United States
HQ region
North America

Markets served

Spatz FGIA business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales

Spatz FGIA product offering

Product offering

Core offering

Spatz FGIA develops and manufactures advanced gastric balloon medical devices for non-surgical weight loss procedures. The company's products are designed with improved safety and patient comfort features to address rising obesity rates. Spatz FGIA, Inc. operates as a key market player in the gastric balloon segment alongside competitors such as Allurion Technologies Inc., Apollo Endosurgery, Inc., and ReShape Lifesciences, Inc.

Product overview

Spatz FGIA is a medical device company focused on gastric balloon systems for non-surgical weight loss. The company develops advanced gastric balloon products designed to address obesity through minimally invasive procedures. Based on available information, Spatz FGIA operates in the gastric balloon market alongside competitors including Allurion Technologies Inc., Apollo Endosurgery, Inc., and ReShape Lifesciences, Inc.

Differentiator

Problem solved

Functional benefit

Products and services

  • Advanced Gastric Balloon Systems

Companies that use Spatz FGIA

Customer profile

Segments1 record

Ideal customer profiles1 record

Spatz FGIA technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Spatz FGIA partnerships and signals

Strategic signal

Scale indicators1 record

Expansion highlights1 record

Spatz FGIA competitors and assessment

Company assessment

Broad incumbents

  • Boston Scientific: Acquired Apollo Endosurgery, bringing scale, sales force, and R&D resources to the endoscopic bariatric and gastric balloon category — overlapping end market and clinician relationships with Spatz FGIA.
  • Medtronic: Broad medtech incumbent with metabolic/obesity franchise (including bariatric surgery and emerging diabetes/weight-loss adjacencies). Overlaps with Spatz FGIA in the obesity-treatment end market.
  • Johnson & Johnson (Ethicon): Major surgical and bariatric stapling franchise through Ethicon, targeting the same obesity-treatment patient population — though via surgical rather than endoscopic approaches.

Direct peers

  • Allurion Technologies: Direct competitor in the gastric balloon space, offering the Allurion (Elipse) swallowable, procedure-less balloon for non-surgical weight loss — directly comparable product and patient population to Spatz FGIA.
  • ReShape Lifesciences: Direct competitor with a gastric balloon product (formerly ReShape and Obalon) targeting the same non-surgical weight-loss market as Spatz FGIA.
  • Apollo Endosurgery: Direct competitor in gastric balloons (Orbera) and endoscopic bariatric devices, now part of Boston Scientific. Competes with Spatz FGIA in the same procedure category and patient base.

Emerging players

  • GI Dynamics: Developer of the EndoBarrier gastrointestinal liner for non-surgical weight loss and type 2 diabetes. Targets an overlapping patient population and minimally invasive obesity-treatment category.
  • USGI Medical: Developer of endoscopic incisionless surgery tools used in bariatric and GI procedures — adjacent technology serving the same non-surgical obesity-treatment patient population as Spatz FGIA.
  • BAROnova: Developer of the TransPyloric Shuttle, an endoscopic device for weight loss. Competes in the same non-surgical endoscopic obesity-treatment category as Spatz FGIA.
  • Aspire Bariatrics: Developer of the AspireAssist aspiration therapy for non-surgical weight loss. Addresses the same obesity-treatment patient population as Spatz FGIA via a different minimally invasive mechanism.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat3 records

Key risks4 records

Key highlights4 records

Customer concentration

Spatz FGIA financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Spatz FGIA leadership team

Management profile

Number of profiles

Spatz FGIA funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Spatz FGIA M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Spatz FGIA

What does Spatz FGIA do?

Spatz FGIA develops and manufactures advanced gastric balloon medical devices for non-surgical weight loss procedures. The company's products are designed with improved safety and patient comfort features to address rising obesity rates. Spatz FGIA, Inc. operates as a key market player in the gastric balloon segment alongside competitors such as Allurion Technologies Inc., Apollo Endosurgery, Inc., and ReShape Lifesciences, Inc.

When was Spatz FGIA founded?

Spatz FGIA was founded in 2005. It employs 51 to 100 people.

Where is Spatz FGIA based?

Spatz FGIA is headquartered in Great Neck, United States, in the North America region.

Who are Spatz FGIA's main competitors?

Broad incumbents on record are Boston Scientific, Medtronic and Johnson & Johnson (Ethicon). Direct peers are Allurion Technologies, ReShape Lifesciences and Apollo Endosurgery. Emerging players are GI Dynamics, USGI Medical, BAROnova and Aspire Bariatrics.

Does Spatz FGIA have an API?

No public API is recorded for Spatz FGIA.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comGastric Balloon Market Size, Share, Growth, Opportunities, Trends, Competitive Insights, Forecast 2027The gastric balloon market was valued at US$ 67.3 million in 2018 and is projected to reach US$ 152.1 million by 2027, growing at a CAGR of 9.7% during the forecast period, driven by rising obesity rates and increasing demand for non-surgical weight loss procedures. Key market players including Allurion Technologies Inc., Apollo Endosurgery, Inc., ReShape Lifesciences, Inc., and Spatz FGIA, Inc. are actively investing in research and development to introduce advanced gastric balloon systems with improved safety and patient comfort. The Asia-Pacific region is expected to witness the fastest growth due to rapid urbanization, changing lifestyles, and increasing healthcare investments in countries like India and China.PharmiWeb.comWeight Management Market Segmentation, Review, Trends, Opportunities, Growth, Demand and Forecast to 2029The global weight management market is projected to grow at a rate of 9-10% by 2029, driven by rising obesity rates, increased bariatric surgeries, fitness awareness, and demand for personalized solutions. Key players including Spatz Medical, ReShape Lifesciences, Allurion Technologies, and Labcorp launched new products and expanded partnerships in 2023-2024, while North America continues to dominate the market with Asia-Pacific poised for significant growth.PharmiWeb.comWeight Management Market Trends, Investment Opportunities, and Growth Analysis Through 2030The global weight management market is projected to grow at a rate of 9-10% by 2029, driven by rising obesity rates and increased demand for medical interventions. Key players such as Spatz Medical, ReShape Lifesciences, and Allurion Technologies are expanding their presence through new product launches and strategic partnerships in regions like the U.S., India, and CEMA.PR NewswireSpatz Medical Marks Milestone: Spatz3 Adjustable Gastric Balloon Launches in the U.S. in March 2024Spatz Medical is launching the Spatz3 Adjustable Gastric Balloon in the U.S. in March 2024, following the successful enrollment completion of the FDA Post Approval Study. This product is recognized for its high success rate of 84% and extraordinary weight loss results, showing a 15% reduction in weight among patients in clinical trials. With innovative adjustability features, the Spatz3 aims to transform the weight loss landscape in bariatric endoscopy.PR NewswireSpatz3 Adjustable Balloon Delivers the Highest Weight Loss ResultsSpatz Medical announced the publication of its FDA pivotal trial results for the Spatz3 Adjustable Balloon in The Lancet, conducted as a 288-patient randomized clinical trial at 7 US centers comparing the device (with diet and exercise) to diet and exercise alone. The trial met all endpoints, with Spatz Balloon patients achieving 15% total body weight loss versus 3.3% in the control group, a 92% clinical response rate, and 74% weight maintenance at 6 months post-extraction. The device's unique adjustability feature allows volume modification during treatment to address weight loss plateau and patient intolerance, with upward adjustment yielding an additional 5.2% weight loss and downward adjustment enabling 75% of intolerant patients to complete therapy.PR NewswireUn año después de la aprobación del gobierno, el balón gástrico ajustable Spatz3 logra el éxito en México y a lo largo de la frontera de EE. UU.Spatz FGIA, Inc. announced that one year after receiving COFEPRIS approval, its Spatz3 adjustable gastric balloon has achieved success in Mexico, exceeding initial projections in both the private and public healthcare sectors. The company highlights Mexico's high obesity rates (56% of Mexico City residents overweight or obese) as a key market driver, with US patients also increasingly using bariatric services along the Mexican border. Spatz notes competitive advantages over the Orbera balloon, including an adjustable volume feature that reduces early removal rates due to intolerance.PR NewswireOne Year After Government Approval, The Spatz3 Adjustable Gastric Balloon Finds Success In Mexico And Along The U.S. BorderSpatz FGIA, Inc. reports that its Spatz3 Adjustable Gastric Balloon has exceeded projected success and acceptance rates in Mexico one year after receiving government approval. The company highlights the device's ability to adjust volume to reduce intolerance-related extractions compared to competitors like Orbera, while also noting potential growth within Mexico's public health system.